Apixaban for Stroke Prevention in a 74-Year-Old Woman With Newly Detected Nonvalvular Atrial Fibrillation: Drug Selection, Monitoring and Teaching
[Author Name]
College of Nursing and Health Care Professions, Grand Canyon University
NUR-635 Advanced Pharmacology
Topic 5 Assignment
[Faculty Name]
August 11, 2026
Composite case written as a model document. No real patient, practice or clinician is described.
The Patient and the Decision
A 74-year-old woman was seen for routine follow-up of hypertension and type 2 diabetes when an irregular pulse was noted at 96 beats per minute. A 12-lead electrocardiogram showed atrial fibrillation with absent P waves, irregularly irregular R-R intervals and a ventricular rate of 96, without acute ischemic change. She reports mild fatigue on stairs over the past two months and denies palpitations, chest pain, breathlessness at rest, dizziness and syncope. Echocardiography reported no valvular stenosis and a left ventricular ejection fraction of 58 percent, which places the arrhythmia in the nonvalvular category the anticoagulation evidence addresses.
History and current therapy: hypertension for 12 years on amlodipine 10 mg daily, with home readings averaging 128/76 mmHg; type 2 diabetes for six years on metformin 1000 mg twice daily, most recent hemoglobin A1C 6.8 percent; atorvastatin 20 mg nightly. She takes ibuprofen 400 mg two or three times in a seven-day span for knee pain, and two months ago she began an over-the-counter St. John's wort preparation for low mood, which she did not count as a medication and had not reported before. She has no prior stroke, transient ischemic attack, gastrointestinal bleeding or intracranial hemorrhage, and no fall in the past year. Weight is 68 kg.
Baseline laboratory values: hemoglobin 13.1 g/dL, platelets 240,000/mm3, serum creatinine 1.1 mg/dL giving a Cockcroft-Gault creatinine clearance near 48 mL/min, with normal aminotransferases and bilirubin. Her CHA2DS2-VASc score is 4, from hypertension, age 65 to 74, diabetes and female sex, and her only modifiable bleeding risk is an over-the-counter analgesic. The decision can therefore be stated in one sentence: whether to anticoagulate, and if so with which agent, at what dose, and with what monitoring. Everything that follows is an argument for one drug at one dose in this specific patient.
The Case for Apixaban Over the Alternatives
The first question is whether to treat at all, and the risk profile answers it. A CHA2DS2-VASc score of 4 carries an annual stroke risk high enough that oral anticoagulation is recommended rather than optional, and current guidance favors a direct oral anticoagulant over warfarin for patients with nonvalvular atrial fibrillation who have no mechanical valve and no moderate to severe mitral stenosis (Joglar et al., 2024). Aspirin is not an alternative here. It gives little protection against the cardioembolic stroke atrial fibrillation produces while still carrying bleeding risk, so offering it as a compromise hands the patient the hazard of a blood thinner without the benefit.
Apixaban is a direct, selective, reversible inhibitor of factor Xa that acts on free enzyme, clot-bound enzyme and enzyme within the prothrombinase complex, so thrombin generation falls while thrombin already formed is untouched (Rosenthal & Burchum, 2021). Oral bioavailability is roughly 50 percent, peak concentration arrives in three to four hours, and the half-life of about 12 hours sets the twice daily schedule. Elimination is mixed: about a quarter renal, the remainder through CYP3A4 metabolism and biliary and intestinal routes, with the molecule a substrate of P-glycoprotein. The labeled dose is 5 mg twice daily, reduced to 2.5 mg twice daily only when two of three criteria are met: age 80 or older, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher (U.S. Food and Drug Administration, 2021). She meets none, so 5 mg twice daily is the dose.
Warfarin remains effective and inexpensive, and it is the correct agent in mechanical valve disease and moderate to severe mitral stenosis, neither of which she has. Against it here are a narrow therapeutic index, a delayed onset that follows the half-lives of factors II, VII, IX and X, dietary vitamin K sensitivity, a long interaction list, and repeated INR testing for a woman who drives herself to every appointment. The head to head evidence matters as well: in a randomized comparison of more than 18,000 patients with atrial fibrillation, apixaban reduced stroke and systemic embolism, caused less major bleeding and lowered mortality relative to warfarin (Granger et al., 2011). Cost is the honest counterweight, and it is answered in the follow-up plan.
Monitoring Plan and Interaction Screen
Apixaban needs no routine coagulation monitoring, which is often misread as needing no monitoring at all. Baseline values are recorded before the first dose: complete blood count, serum creatinine with a calculated creatinine clearance, and a hepatic panel. Renal function is rechecked at least annually and sooner during any illness that cuts intake or increases losses, because a creatinine clearance near 48 mL/min sits close enough to the reduction thresholds that a dehydrating illness could move her across one. Hemoglobin is repeated at six months and with any reported bleeding. Blood pressure is reviewed at every visit, since uncontrolled pressure raises stroke risk and intracranial bleeding risk at once.
The interaction screen was run against her actual list rather than in the abstract, and it produced one urgent finding. St. John's wort induces CYP3A4 and P-glycoprotein and can lower plasma concentrations of drugs cleared by those routes, which in an anticoagulant means the silent failure of stroke prevention rather than a symptom she would notice (National Center for Complementary and Integrative Health, 2020). It was stopped before the first dose and her low mood was addressed on its own terms. Ibuprofen is the second finding, adding platelet inhibition and gastric mucosal injury to an anticoagulant, a combination the current criteria for older adults advise against without a strong indication (American Geriatrics Society Beers Criteria Update Expert Panel, 2023).
Two further categories are documented so a later prescriber does not have to rediscover them. Strong dual inhibitors of CYP3A4 and P-glycoprotein, including ketoconazole, itraconazole, ritonavir and clarithromycin, raise apixaban exposure and call for a different agent or a labeled adjustment. Strong inducers such as rifampin, carbamazepine and phenytoin lower exposure enough that the pairing is avoided. Amlodipine, atorvastatin and metformin need no change. The plan also names what would prompt a rethink: a fall with head strike, a hemoglobin drop of 2 g/dL, new anemia, a creatinine clearance below 25 mL/min, or a scheduled procedure needing a documented pause and restart date.
Patient Teaching and Follow-Up
Teaching was given in plain language and confirmed by teach-back rather than by a yes or no answer. She repeated the plan in her own words: one tablet in the morning and one at night about 12 hours apart, with or without food; a missed dose taken as soon as she remembers on the same day and never two at once; and no stopping for any reason without speaking to the prescriber first, including before dental work. She was told plainly that the drug is preventing a stroke she cannot feel coming, which is the reason a silent medication still has to be taken on time.
Bleeding education was specific rather than general. She was asked to report black or tarry stools, red or brown urine, coughing or vomiting blood, bruising that spreads without an injury, a nosebleed that will not stop after 15 minutes of pressure, and any fall in which she strikes her head even if she feels well afterward, because bleeding inside the skull can begin slowly. An anticoagulant card for her wallet was completed with the drug name, the dose and the prescriber's number. The existence of a reversal agent in hospital settings was explained once, in the context of emergency care rather than as grounds for complacency.
Access was treated as part of the prescription. A 90-day supply through a single pharmacy was arranged so interaction checking happens in one place, the copay was confirmed before she left, and the manufacturer assistance route was documented in case her coverage changes, since an anticoagulant abandoned over cost is more dangerous than one never started. Her own priorities are recorded because they shaped the choice: she intends to keep driving herself and to keep taking a neighbor to church on Sundays, which made an agent without routine INR visits and dietary restriction the better fit for the life she means to keep. Follow-up is set at one month, with rate control reviewed then.
References
American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081.
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., Bahit, M. C., Diaz, R., Easton, J. D., Ezekowitz, J. A., Flaker, G., Garcia, D., Geraldes, M., Gersh, B. J., Golitsyn, S., ... Wallentin, L. (2011). Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 365(11), 981-992.
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., ... Van Wagoner, D. R. (2024). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation, 149(1), e1-e156.
National Center for Complementary and Integrative Health. (2020). St. John's wort and depression: In depth. National Institutes of Health. https://www.nccih.nih.gov/health/st-johns-wort-and-depression-in-depth
Rosenthal, L. D., & Burchum, J. R. (2021). Lehne's pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.). Elsevier.
U.S. Food and Drug Administration. (2021). Highlights of prescribing information: Eliquis (apixaban) tablets. https://www.accessdata.fda.gov/scripts/cder/daf/
How this NUR 635 Topic 5 example is structured
Grand Canyon University does not publish topic-by-topic deliverable names, so treat this NUR-635 Topic 5 example as a model of the genre rather than a copy of one classroom's prompt. In many sections this topic asks for a drug therapy paper that defends one agent for one patient; your classroom's instructions and rubric decide the exact form. The paper runs in four sheets and is built as an argument. The first sheet states the patient and the exact decision to be made, so the reader knows what is being defended. The second sheet makes the case for the chosen drug and against the alternatives, using pharmacology rather than preference. The third sheet holds the monitoring plan and an interaction screen run against her real list. The fourth records the teaching and the follow-up.
NUR-635 Topic 5 questions, answered
What does the NUR-635 Topic 5 assignment usually ask for?
Grand Canyon University does not publish topic-by-topic deliverable names for this course, so read your classroom's instructions and rubric first. In many sections this topic asks for a drug therapy paper that selects one agent for one patient and defends it with pharmacology, monitoring, interactions and teaching. The example on this page is written as that genre from start to finish.
How do I defend a drug choice instead of just describing the drug?
Name the alternatives and beat them on the record. Say why the class is right, why this agent inside the class, and why this dose, using a labeled criterion or a guideline recommendation applied to your patient's own numbers. Include the strongest objection, such as cost, and answer it. A paper that only praises the chosen drug reads as a package insert.
Does a pharmacology paper need patient teaching and monitoring sections?
Almost always, because prescribing rubrics grade the whole decision rather than the choice alone. Give each monitoring test an interval and a reason, tie interaction checks to the medications your patient actually takes, and write teaching in the words a patient would hear. Specific instructions, thresholds and follow-up dates earn credit that general safety statements never do.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Grand Canyon University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.